Patient access schemes in Asia-pacific markets:Current experience and future potential

Journal of Pharmaceutical Policy and Practice

Volumn 8, Issue 1, 2015, Pages 1-12

  Lu, Christine Y ^a   Lupton, Caitlin ^a   Rakowsky, Shana ^b   Babar, Zaheer Ud Din ^c   Ross Degnan, Dennis ^a   Wagner, Anita K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Access to medicines; Conditional coverage; Health technology assessment; High cost medicines; Managed entry; Patient access schemes; Risk sharing

Indexed keywords

ARTICLE; ASIA; AUSTRALIA; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG INDICATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE NEED; HUMAN; NEW ZEALAND; OUTCOME ASSESSMENT; REIMBURSEMENT; RHEUMATOID ARTHRITIS; RISK MANAGEMENT; SOUTH KOREA;

EID: 84983158143     PISSN: None     EISSN: 20523211     Source Type: Journal    
DOI: 10.1186/s40545-014-0019-x     Document Type: Article

References (39)

1. Tangcharoensathien V, Patcharanarumol W, Ir P, Aljunid S, Mukti A, Akkhavong K, et al. Health-financing reforms in Southeast Asia: challenges in achieving universal coverage. Lancet. 2011; 377(9768): 863-73.
2. World Health Organization: What is Universal Health Coverage? http: //www. who. int/features/qa/universal_health_coverage/en/. Accessed February 23, 2015.
3. Freemantle N, Hill S. Evaluating Pharmaceuticals for Health Policy and Reimbursement. Oxford, UK: Blackwell; 2004.
4. Lu CY, Williams K, Day R, March L, Sansom L, Bertouch J. Access to high cost drugs in Australia. BMJ. 2004; 329(7463): 415-6.
5. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012; 15(3): 570-9.
6. Sansom L. The subsidy of pharmaceuticals in Australia: processes and challenges. Aust Health Rev. 2004; 28(2): 194-205.
7. Jirawattanapisal T, Kingkaew P, Lee TJ, Yang MC. Evidence-based decisionmaking in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan. Value Health. 2009; 12 Suppl 3: S4-S11.
8. Thatte U, Hussain S, de Rosas-Valera M, Malik MA. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan. Value Health. 2009; 12 Suppl 3: S18-25.
9. Teerawattananon Y, Tantivess S, Yothasamut J, Kingkaew P, Chaisiri K. Historical development of health technology assessment in Thailand. Int J Technol Assess Health Care. 2009; 25 Suppl 1: 241-52.
10. PHARMAC: Prescription for Pharmacoeconomic Analysis: Methods for costutility analysis. 2012; http: //www. pharmac. health. nz/assets/pfpa-final. pdf. Accessed February 23, 2015.
11. Towse A, Garrison Jr LP. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performancebased risk-sharing agreements for innovative medical products. Pharmacoeconomics. 2010; 28(2): 93-102.
12. Lu CY. Uncertainties in real-world decisions on medical technologies. Int J Clin Pract. 2014; 68(8): 936-40.
13. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010; 96(3): 179-90.
14. Australian Government Department of Human Services: Complex Authority Required Highly Specialised Drugs (CAR HSD). http: //www. humanservices. gov. au/health-professionals/services/highly-specialised-drugs/. Accessed February 23, 2015.
15. Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics. 2010; 28(2): 113-42.
16. Australian Government Department of Health: Pharmaceutical Benefits Scheme Schedule. http: //www. pbs. gov. au/pbs/home. Accessed February 23, 2015.
17. Australian Government Department of Health: Therapeutic Relativity Sheets. http: //pbs. gov. au/info/industry/pricing/pbs-items/therapeutic-relativitysheets. Accessed February 23, 2015.
18. Australian Government Department of Health: Public Summary Documents. http: //www. pbs. gov. au/pbs/industry/listing/elements/pbac-meetings/psd. Accessed February 23, 2015.
19. Robertson J, Walkom EJ, Henry DA. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. Aust Health Rev. 2009; 33(2): 192-9.
20. Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010; 10: 153.
21. Pugatch M, Healy P, Chu R: Sharing the Burden: Could Risk-Sharing Change the Way We Pay for Healthcare? The Stockholm Network; 2010. http: //www. stockholm-network. org/downloads/publications/Sharing_the_Burden. pdf. Accessed February 23, 2015.
22. Lee EK, Kim BY, Lim JY, Park MH. Different policy outcomes of the new drugs and currently listed drugs under the positive list system in South Korea. Value Health. 2012; 15(1 Suppl): S100-3.
23. Raftery JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust. 2008; 188(1): 26-8.
24. Antonanzas F, Juarez-Castello C, Rodriguez-Ibeas R. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econ Policy Law. 2011; 6(3): 391-403.
25. Access Economics Pty Limited. The Economic Cost of Arthritis in New Zealand in 2010: Arthritis New Zealand; 2010. http: //www. arthritis. org. nz/wp-content/ uploads/2011/07/economic-cost-of-arthritis-in-new-zealand-final-print. pdf. Accessed February 23, 2015.
26. PHARMAC: Decision Criteria. http: //www. pharmac. health. nz/medicines/ how-medicines-are-funded/decision-criteria/. Accessed February 23, 2015.
27. Yang BM, Bae EY, Kim J. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance. Health Aff. 2008; 27(1): 179-87.
28. Lu CY, Williams KM, Day RO. Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target? Intern Med J. 2006; 36(1): 19-27.
29. Owen A, Spinks J, Meehan A, Robb T, Hardy M, Kwasha D, et al. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. J Med Econ. 2008; 11(2): 235-43.
30. Lu CY, Williams KM, Day RO. Accessing health outcome data on high-cost medicines in Australia. Med J Aust. 2006; 184(8): 411-3.
31. Lu CY, Ritchie J, Williams K, Day R. The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia. Austr N Z Health Policy. 2007; 4: 26.
32. Lu CY, Williams KM, Day RO. The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines. Austr N Z Health Policy. 2007; 4: 2.
33. Lu CY, Macneill P, Williams K, Day R. Access to high cost medicines in Australia: ethical perspectives. Austr N Z Health Policy. 2008; 5: 4.
34. Lu CY, Williams KM, March L, Bertouch JV, Day RO. Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible? Med J Aust. 2004; 181(8): 457. discussion 457-458.
35. McCabe CJ, Stafinski T, Edlin R, Menon D, Banff AEDS. Access with evidence development schemes: a framework for description and evaluation. Pharmacoeconomics. 2010; 28(2): 143-52.
36. Lassarat S, Jootar S. Ongoing challenges of a global international patient assistance program. Ann Oncol. 2006; 17 Suppl 8: viii43-6.
37. Ministry of Public Health. Notification of the Ministry of Public Health: Re: Exercising of right on pharmaceuticals products patent for imatinib, dated 25th January, B. E. 2551. Nonthaburi: Ministry of Public Health; 2008.
38. IMS Institute for Healthcare Informatics: The Global Use of Medicines: Outlook through 2017. 2013; http: //www. imshealth. com/deployedfiles/imshealth/ Global/Content/Corporate/IMS%20Health%20Institute/Reports/Global_ Use_of_Meds_Outlook_2017/IIHI_Global_Use_of_Meds_Report_2013. pdf. Accessed February 23, 2015.
39. Lu CY, Williams K, Day R. Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia. Int J Rheum Dis. 2008; 11: 11-4.